lung cancer

Examining Genetic Influences on Lung Cancer

IRP Research Investigates Disease’s Roots Beyond Smoking

magnifying glass examining DNA in the lungs

Today is World Lung Cancer Day, bringing increased awareness to a disease most commonly associated with smoking tobacco products. Yet even though cigarette smoking rates have decreased over the past few decades, this deadly disease remains responsible for more deaths than any other type of cancer — more than 125,000 per year in the U.S. alone. In fact, between 10 and 25 percent of lung cancers occur in people who never smoked.

IRP Stadtman Investigator Jiyeon Choi, Ph.D., has always been curious about how our DNA influences the traits we have and our risk for diseases. When it comes to genes’ contribution to cancer risk, the stakes are particularly high, but Dr. Choi noticed a gap in research when it came to understanding the role genetic variation plays in lung cancer risk. She and her research team aim to fill this gap using a battery of high-tech genomic studies to root out the genes and molecular processes that make some people more susceptible to the disease.

Predicting Risks and Benefits for Lung Cancer Screening

IRP Researchers Refine Tools to Maximize the Benefit from Life-Saving Tests

patient getting a CT scan

Eleven years ago, IRP senior investigator Hormuzd Katki, Ph.D., had a bit of an eureka moment during a press event announcing the results of the National Lung Cancer Screening Trial, which demonstrated that annual screenings cut the risks of dying from lung cancer in heavy smokers by 20 percent.

“It struck me as I read the trial results that not only was this a very important trial, but that it was possible that different people will have different benefits from lung cancer screening,” Dr. Katki remembers. “Even within this group of very high-risk smokers who were part of the trial, you can identify some people who get much more benefit than other people, and that has implications for who should be offered this kind of screening.”